Uterotonics for Severe Preeclampsia

Carbetocin Versus Combined Oxytocin and Misoprostol for Prevention of Postpartum Hemorrhage in Women With Severe Preeclampsia

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04756661

Enrollment

124

Registered

2021-02-16

Start date

2020-01-01

Completion date

2021-02-10

Last updated

2021-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preeclampsia Severe

Brief summary

The study compares the effect of Intravenous carbetocin versus combined use of intravenous oxytocin and rectal misoprostol for prevention of postpartum hemorrhage during delivery of women with severe preeclampsia

Interventions

DRUGCarbetocin

100 mcg of Carbetocin intravenous injection

DRUGOxytocin

10 IU oxytocin IV drip

DRUGMisoprostol

400 mcg rectal

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

FEMALE

Healthy volunteers

Inclusion criteria

* Pregnant women which diagnosed with severe pre-eclampsia. * Singleton pregnancy. * Termination of pregnancy by Cesarean section after 28 weeks of gestation.

Exclusion criteria

* Suspected or proven placental abruption. * Known placenta Previa or acreata. * Multiple pregnancies. * Obesity (BMI \>35). * Anemia (\<9 g/dl). * Retained placental tissues. * Big baby (\> 4 kg). * Presence of coagulopathy. * Polyhydramnios. * Presence of Uterine fibroids. * Medical diseases as; cardiac, liver, renal or endocrine diseases. * General anesthesia.

Design outcomes

Primary

Measure	Time frame	Description
The rate of postpartum hemorrhage more than 1000 ml	30 minutes	the amount of bleeding during and after CS

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026